How does the drug resmetirom work?

Resmetirom-Rezdiffra, as one of the world's first oral drugs specifically targeted at non-alcoholic steatohepatitis (NASH), has shown outstanding potential in research and clinical application in recent years. NASH is a chronic liver disease related to metabolism that often coexists with obesity, diabetes, lipid metabolism disorders and other problems. Moderate to severe liver fibrosis is prone to occur during the course of the disease. Once it progresses to cirrhosis, it often poses a serious threat to the patient's health. The emergence of resmetirol has filled the gap of limited NASH treatment options for a long time.

The mechanism of action of this drug is mainly related to the agonistic effect of thyroid hormone receptorβ (THR-β). It can selectively act on liver tissue to promote the improvement of lipid metabolism, thereby reducing liver fat accumulation, improving inflammatory response, and delaying the progression of fibrosis. Compared with traditional lifestyle intervention or other drug support, resmetirol provides a more direct and targeted treatment path. Clinical data show that it can not only reduce liver fat content, but also improve inflammatory activity and fibrosis in some patients. This combined effect is of great significance in delaying disease progression.

One of the advantages of resmetirol is its oral administration form, which enables higher patient compliance and facilitates long-term treatment. At the same time, compared with some traditional drugs, the drug shows additional benefits in weight control and metabolic improvement, and is especially suitable for NASH patients with metabolic syndrome or diabetes. In the study, many patients also experienced corresponding improvements in serum liver function indicators and metabolic parameters after using the drug, which provides more reference value for clinicians.

Nonetheless, the efficacy of resmetirol varies, and not all patients experience significant improvement. The condition of some patients may show different degrees of response due to different basic metabolic conditions, concomitant diseases or lifestyle.

Reference materials:https://www.drugs.com/monograph/resmetirom.html